{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:51:01Z","timestamp":1788360661222,"version":"build-2803163510"},"reference-count":58,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Thrombotic complications are the primary contributor to morbidity and mortality in essential thrombocythemia (ET) and polycythemia vera (PV). Cytoreductive therapy is the main tool for primary or tertiary thrombosis prevention in these diseases. In general, high-thrombotic-risk patients and those with symptoms that may be ameliorated from cytoreductive therapy are candidates for this treatment, although the decision is highly individualized. Approved options for cytoreduction in ET and PV include hydroxyurea, long-acting interferons, anagrelide in ET, and ruxolitinib in PV. Selecting the ideal agent requires careful consideration of the toxicity profiles and individual treatment goals. In this review the existing literature on cytoreductive decisions in ET and PV is summarized, with an emphasis on risk-stratification, highlighting the need for personalized care in order to maximize the benefit of these therapies while minimizing toxicities.<\/jats:p>","DOI":"10.1182\/hematology.2023000451","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:14:21Z","timestamp":1702048461000},"page":"660-666","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Cytoreduction for ET and PV: who, what, when, and how?"],"prefix":"10.1182","volume":"2023","author":[{"given":"Douglas","family":"Tremblay","sequence":"first","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"issue":"7","key":"2023120815083140800_hem2023000451C1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"2023120815083140800_hem2023000451C2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00277-023-05089-6","article-title":"Real-world treatments and thrombotic events in polycythemia vera patients in the USA","volume":"102","author":"Verstovsek","year":"2023","journal-title":"Ann Hematol"},{"key":"2023120815083140800_hem2023000451C3","doi-asserted-by":"crossref","first-page":"106809","DOI":"10.1016\/j.leukres.2022.106809","article-title":"Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia","volume":"115","author":"Pemmaraju","year":"2022","journal-title":"Leuk Res"},{"key":"2023120815083140800_hem2023000451C4","unstructured":"Gerds\n              AT\n            , GotlibJ, AliH, et al.\n          Myeloproliferative Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. Vols. 2-23. Plymouth Meeting, PA: National Comprehensive Cancer Network; 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpn.pdf. Accessed April7, 2023."},{"issue":"5","key":"2023120815083140800_hem2023000451C5","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"2023120815083140800_hem2023000451C6","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","article-title":"Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations","volume":"9","author":"Marchetti","year":"2022","journal-title":"Lancet Haematol"},{"issue":"10","key":"2023120815083140800_hem2023000451C7","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.6004\/jnccn.2017.0157","article-title":"NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018","volume":"15","author":"Mesa","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"2023120815083140800_hem2023000451C8","article-title":"Myeloproliferative Neoplasms","author":"NCCN Guidelines Version 2.2021","year":"2021"},{"issue":"10","key":"2023120815083140800_hem2023000451C9","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"issue":"26","key":"2023120815083140800_hem2023000451C10","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-Essential Thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2023120815083140800_hem2023000451C11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study","volume":"168","author":"Hultcrantz","year":"2018","journal-title":"Ann Intern Med"},{"issue":"2","key":"2023120815083140800_hem2023000451C12","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/sj.leu.2401270","article-title":"Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients","volume":"13","author":"Besses","year":"1999","journal-title":"Leukemia"},{"issue":"8","key":"2023120815083140800_hem2023000451C13","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1002\/ajh.23743","article-title":"Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am J Hematol"},{"issue":"10","key":"2023120815083140800_hem2023000451C14","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2023120815083140800_hem2023000451C15","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment","volume":"120","author":"Passamonti","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2023120815083140800_hem2023000451C16","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"2023120815083140800_hem2023000451C17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera","volume":"189","author":"Tefferi","year":"2020","journal-title":"Br J Haematol"},{"issue":"10","key":"2023120815083140800_hem2023000451C18","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s00277-017-3082-y","article-title":"The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey","volume":"96","author":"Harrison","year":"2017","journal-title":"Ann Hematol"},{"issue":"6","key":"2023120815083140800_hem2023000451C19","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/ejh.12645","article-title":"Non-anaemic iron deficiency\u2014a disease looking for recognition of diagnosis: a systematic review","volume":"96","author":"Pratt","year":"2016","journal-title":"Eur J Haematol"},{"issue":"19","key":"2023120815083140800_hem2023000451C20","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1182\/blood.2019003347","article-title":"Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis","volume":"135","author":"Ronner","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2023120815083140800_hem2023000451C21","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1080\/10428194.2022.2156794","article-title":"Leukocytosis and MPNs: where do we stand?","volume":"64","author":"Coltoff","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2023120815083140800_hem2023000451C22","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/bloodadvances.2019000211","article-title":"Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis","volume":"3","author":"Carobbio","year":"2019","journal-title":"Blood Adv"},{"issue":"February","key":"2023120815083140800_hem2023000451C23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","article-title":"Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey","volume":"16","author":"Mesa","year":"2016","journal-title":"BMC Cancer"},{"issue":"3","key":"2023120815083140800_hem2023000451C24","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/ajh.24269","article-title":"Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: evaluation on 1,297 patients","volume":"91","author":"Andriani","year":"2016","journal-title":"Am J Hematol"},{"issue":"5","key":"2023120815083140800_hem2023000451C25","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"2023120815083140800_hem2023000451C26","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","article-title":"Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial","volume":"8","author":"Barbui","year":"2021","journal-title":"Lancet Haematol"},{"issue":"1","key":"2023120815083140800_hem2023000451C27","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(21)00343-4","article-title":"Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials","volume":"9","author":"Mazza","year":"2022","journal-title":"Lancet Haematol"},{"issue":"17","key":"2023120815083140800_hem2023000451C28","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"issue":"34","key":"2023120815083140800_hem2023000451C29","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1200\/JCO.2018.78.8414","article-title":"Hydroxycarbamide plus aspirin versus aspirin alone in patients with essential thrombocythemia age 40 to 59 years without high-risk features","volume":"36","author":"Godfrey","year":"2018","journal-title":"J Clin Oncol"},{"issue":"18","key":"2023120815083140800_hem2023000451C30","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2019000428","article-title":"Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea","volume":"134","author":"Yacoub","year":"2019","journal-title":"Blood"},{"issue":"19","key":"2023120815083140800_hem2023000451C31","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia","volume":"139","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"key":"2023120815083140800_hem2023000451C32","unstructured":"Knudsen\n              T\n            , HansenD, OciasL, et al.\n          Three-year analysis of the Daliah trial\u2014a randomized controlled phase III clinical trial comparing recombinant interferon alpha-2 vs. hydroxyurea in patients with myeloproliferative neoplasms. Paper presented at: European Hematology Association Annual Meeting: Amsterdam; 2019. https:\/\/library.ehaweb.org\/eha\/2019\/24th\/267363\/trine.alma.knudsen.three-year.analysis.of.the.daliah.trial.-.a.randomized.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D1%2Amedia%3D1"},{"issue":"7","key":"2023120815083140800_hem2023000451C33","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1182\/bloodadvances.2021004856","article-title":"Genomic profiling of a randomized trial of interferon-\u03b1 vs hydroxyurea in MPN reveals mutation-specific responses","volume":"6","author":"Knudsen","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"2023120815083140800_hem2023000451C34","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1182\/blood.V99.5.1602","article-title":"Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia","volume":"99","author":"Tomer","year":"2002","journal-title":"Blood"},{"issue":"1","key":"2023120815083140800_hem2023000451C35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"2023120815083140800_hem2023000451C36","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2023120815083140800_hem2023000451C37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9343(92)90017-6","article-title":"Anagrelide, a therapy for thrombocythemic states: experience in 577 patients","volume":"92","author":"Anagrelide Study Group","year":"1992","journal-title":"Am J Med"},{"issue":"11","key":"2023120815083140800_hem2023000451C38","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/ajh.24851","article-title":"A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity-matched study","volume":"92","author":"Barbui","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"2023120815083140800_hem2023000451C39","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol"},{"issue":"19","key":"2023120815083140800_hem2023000451C40","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1200\/JCO.22.01935","article-title":"Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial","volume":"41","author":"Harrison","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"2023120815083140800_hem2023000451C41","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/bloodadvances.2019001158","article-title":"Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis","volume":"4","author":"Masciulli","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"2023120815083140800_hem2023000451C42","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s00277-014-2152-7","article-title":"Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea","volume":"93","author":"Alvarez-Larr\u00e1n","year":"2014","journal-title":"Ann Hematol"},{"issue":"7","key":"2023120815083140800_hem2023000451C43","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"issue":"November","key":"2023120815083140800_hem2023000451C44","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1182\/blood-2018-99-111255","article-title":"Long-term efficacy and safety of recombinant interferon alpha-2 vs. hydroxyurea in polycythemia vera: preliminary results from the three-year analysis of the Daliah trial\u2014a randomized controlled phase III clinical trial","volume":"132","author":"Knudsen","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2023120815083140800_hem2023000451C45","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"issue":"9","key":"2023120815083140800_hem2023000451C46","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41375-021-01183-8","article-title":"Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival","volume":"35","author":"Abu-Zeinah","year":"2021","journal-title":"Leukemia"},{"issue":"23","key":"2023120815083140800_hem2023000451C47","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2023120815083140800_hem2023000451C48","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2141.2010.08430.x","article-title":"Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance\/intolerance to hydroxycarbamide in essential thrombocythaemia: hydroxycarbamide in essential thrombocythaemia","volume":"152","author":"Hern\u00e1ndez-Boluda","year":"2011","journal-title":"Br J Haematol"},{"issue":"6","key":"2023120815083140800_hem2023000451C49","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00277-013-1683-7","article-title":"Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide","volume":"92","author":"Hern\u00e1ndez-Boluda","year":"2013","journal-title":"Ann Hematol"},{"issue":"6","key":"2023120815083140800_hem2023000451C50","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Alvarez-Larr\u00e1n","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2023120815083140800_hem2023000451C51","doi-asserted-by":"crossref","first-page":"e721","DOI":"10.1097\/HS9.0000000000000721","article-title":"European LeukemiaNet response predicts disease progression but not thrombosis in polycythemia vera","volume":"6","author":"Tremblay","year":"2022","journal-title":"HemaSphere"},{"issue":"7","key":"2023120815083140800_hem2023000451C52","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort","volume":"120","author":"Campbell","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2023120815083140800_hem2023000451C53","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.6004\/jnccn.2020.7595","article-title":"What's in a number? Examining the prognostic and predictive importance of platelet count in patients with essential thrombocythemia","volume":"18","author":"Kuykendall","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2023120815083140800_hem2023000451C54","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3324\/haematol.2016.152769","article-title":"Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea","volume":"102","author":"Alvarez-Larr\u00e1n","year":"2017","journal-title":"Haematologica"},{"issue":"5","key":"2023120815083140800_hem2023000451C55","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.3324\/haematol.2015.139691","article-title":"Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series","volume":"101","author":"Beauverd","year":"2016","journal-title":"Haematologica"},{"key":"2023120815083140800_hem2023000451C56","article-title":"Outcomes of 121 pregnancies in patients with polycythemia vera (PV). Haematologica","author":"Griesshammer","year":"2016"},{"issue":"5","key":"2023120815083140800_hem2023000451C57","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/bloodadvances.2022008259","article-title":"Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea","volume":"7","author":"Wang","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"2023120815083140800_hem2023000451C58","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1586\/ehm.11.63","article-title":"A new era for IFN-\u03b1 in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms","volume":"4","author":"Hasselbalch","year":"2011","journal-title":"Expert Rev Hematol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/660\/2175794\/660tremblay.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/660\/2175794\/660tremblay.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:14:41Z","timestamp":1702048481000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2023\/1\/660\/506419\/Cytoreduction-for-ET-and-PV-who-what-when-and-how"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,8]]},"published-print":{"date-parts":[[2023,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2023000451","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,8]]},"published":{"date-parts":[[2023,12,8]]}}}